Liquid Biopsy Technology to Improve Prostate Cancer Treatment

by Chrisy Ngilneii on  April 3, 2018 at 4:32 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

A new liquid biopsy technology for prostate cancer can identify which patient will respond to treatment well and who will not. This helps in decision making regarding treatments as patients with high mRNA expression may not respond to the first-line treatment. This technology is developed by a research team at the University of Toronto.
Liquid Biopsy Technology to Improve Prostate Cancer Treatment
Liquid Biopsy Technology to Improve Prostate Cancer Treatment

"Screening for drug resistance is key to improving treatment approaches for many cancers," said Shana Kelley, scientist and professor at the Leslie Dan Faculty of Pharmacy, University of Toronto. "It's important for patients not to be on a therapy that won't help them and it's also important for healthcare systems to avoid, whenever possible, delivering ineffective treatments."

Show Full Article


The ability to screen patients using a blood sample as opposed to more invasive techniques required for conventional biopsies is also a step forward.

Kelley, lead investigator on the study published in Nature Chemistry, explained how her team has advanced a completely new approach using magnetic nanoparticles with DNA capture probes on their surface that can target circulating tumor cells (CTCs) in blood samples to see if the cells contains biomarkers associated with drug resistance. "We can then trap the individual magnetized cells in a microfluidic device built in the lab, isolating them from all the other cells in the sample and allowing us to perform highly sensitive analysis," Kelley said. The cells with the highest magnetic content will also have high mRNA expression for the biomarker associated with drug resistance.

"This means that patients with high mRNA expression should be considered for other therapies because they won't respond to the first-line treatment."

Targeting CTCs, the cells responsible for spreading cancer, is important because they carry information from the primary tumor that can inform treatment; however, they are outnumbered by a billion-to-one by normal cells in a patient' blood and are therefore extremely challenging to capture. In 2016, Kelley and her team published a study in Nature Nanotechnology that first introduced the microfluidic device and how it could be used to trap and analyze CTCs. The current study builds on this previous work by further targeting a specific biomarker within the CTCs.

The blood samples analyzed were collected from a small cohort of patients undergoing treatment for metastatic prostate cancer. In 10 of the patients tested, CTCs were visualized but only four of the patients exhibited the biomarker associated with drug resistance. This finding demonstrates that the new method can provide both a CTC count and an analysis of the clinically relevant biomarker.

"We are very excited because this is like finding a needle in a haystack. It paves the way for a straightforward and personalized screening tool that allows clinicians to see if a patient will respond to therapy or not. Our method is also rapid, accurate and inexpensive, which gives it real potential for clinical uptake," said Kelley.

As for next steps, the finding must be replicated in a larger study, Kelley explained. Her team is also focused on "scaling up" and expanding the application of this technology to other forms of cancer and other diseases.

"Liquid biopsy is one of the most promising tools emerging for the management of cancer," said Kelley "and we are excited about the potential of our technology to streamline this type of testing."

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive